CDX Models for Oncology Studies

Our cell line-derived xenograft (CDX) model studies can be offered as subcutaneous, disseminated, or orthotopic in both mice and rats, and can also be used in our humanized models for evaluating immunotherapies within an intact human immune system.

Cell Line-Derived Xenograft - Cancer Model Database

Micropathology of breast tumor model, to represent the tumor models available in Charles River’s Cancer Model Database.

Support your in vitro, in vivo, and ex vivo studies with the following at your fingertips:

  • New user-friendly search and easy-to-navigate menus
  • New model data, including HLA typing, growth curves, and tumor images
  • New multi-parameter search options for all tumor model types (PDX and CDX)

Visit our Database

Human tumor CDX models involve implantation of commercially available tumor cell lines or patient-derived xenograft-derived cell lines into immunodeficient mice to conduct in vivo efficacy evaluation of potential cancer therapies, including targeted therapy, cytotoxic drugs, antibody therapies, and viral therapies.

Our broad range of tumor lines gives you a wide variety of testing alternatives for your agent. We evaluate our xenograft model portfolio on a regular basis for response to standards of care to aid the design of combination studies.

Tumor cell lines from commercial vendors or from patient-derived xenografts are engrafted into immunodeficient mice. The resulting tumor model is used to test targeted therapy, cytotoxic drugs, antibody therapies and viral therapies.
Figure 1: Schematic of Cell Line-Derived Xenograft, CDX Model

In addition to helping you select the most appropriate CDX model for your agent, our scientific staff can fully profile your agent in a variety of tumor types or in combination with the appropriate clinical agent.

Charles River offers a wide range of histotypes, including broad models like non-small cell lung cancer, breast cancer or colon cancer, as well as tumor models with a high medical need like ovarian cancer, leukemia, lymphoma, or prostate cancer.

    Histotype Cell Line*
    Bladder SW780
    Brain SK-N-AS, U87 MG, U251
    Breast BT474, HCC-1806, HCC-1954, JIMT-1, MCF-7, MDA-MB-231, HCC70, MDA-MB436
    Colon CL-34, COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo, LS-174T, LS411N, RKO, SW48, SW480, SW620
    Endocervical KB
    Epithelial A-431
    Ewing's Sarcoma RD-ES
    Gastric N87, SNU-5, OE19
    Head and Neck FaDu
    Leukemia HL-60, MOLM-13, MOLT-4, MV4-11, RS4;11, SET2, THP-1, HEL92.1.7, Kasumi-1, K562, OCI-AML3
    Liver HuH-7, SNU-398, Hep3B
    Lung (Non-small cell) A-427, A549, H1299, H1975, H226, H23, H292, H460, H520, H522, H647, H727, H810, HCC-44, NCI-H2122, H1568, SK-MES-1, H1650
    Lung (Small cell) H69, H82, H211, H526, SHP-77, DMS 114
    Lymphoma Daudi, DoHH-2, Granta 519, JEKO-1, KARPAS-299, Mino, MOLT-4, Raji B, Ramos, REC-1, RL, SU-DHL-4, WSU-DLCL2, Namalwa
    Melanoma A2058, A375, IGR-37, UACC-62
    Mesothelioma MSTO-211H
    Multiple Myeloma H929, OPM-2, RPMI 8226
    Neuroblastoma SKNAS
    Ovarian A2780, IGR0V1, OVCAR-3, OVCAR-5, SK-OV-3, TOV-21G, OV-90
    Pancreas BxPc-3, HPAC, HPAF II, KP4, MIA PaCa-2, PSN-1, PANC1
    Prostate 22Rv.1, PC3
    Renal 786-0, G-401, G-402
    Sarcoma HT-1080, SJSA-1
    Thyroid 8505C, FTC-238
    Uterine ECC-1, MFE-280
    * Note: Specially requested lines can be developed if a model of interest is not among those listed above.

    Although the models listed below have not yet been profiled for response to current standards of care, tumor growth curve data is available.

    Histotype Cell Line*
    Adrenal H295R
    Gastric MKN-45
    Lung COR-L23, NCI-H1963, H2009, H1581, H1993, H441
    Melanoma CHL-1, COLO 800, IGR-1, IGR-37
    Multiple Myeloma MM1.s, KMS-11
    Prostate DU145, LNCaP, VCaP
    Thyroid K1
    Uterine HEC-1-A, HEC-1-B
    * Note: Specially requested lines can be developed if a model of interest is not among those listed above.

Efficacy evaluation in CDX models can be combined with:

  • Hematology (CBC/Diff) analysis
  • Pharmacokinetic or bioavailability sampling and analysis
  • Histopathology or tissue sampling
  • Biomarker screening, sampling, or evaluation
  • In vivo microdialysis to determine pharmacological effects with high sensitivity and temporal resolution


Graph showing HCT116 colon carcinoma standard of care data, showing the output of Charles Rivers extensive Standard of Care Database for use in combination design in cell-line derived xenograft CDX models.
Figure 2: Charles River’s CDX models have extensive standard of care data for combination design

On Demand Oncology Webinar

Multichannel pipette injecting liquid into a microtiter plate for oncology research.

Integrated Approaches: Leveraging In Vitro and Ex Vivo Tools for Oncology Research.
Watch the Webinar

If you’re looking to purchase oncology research models for use in your own efficacy studies, please visit our research models pages or see our xenograft data collection for help in selecting the best animal model.

Sign up for the Oncology Fast 5 Monthly Newsletter for latest in oncology news.

Frequently Asked Questions (FAQs) for CDX Models: